Abstract: Described herein are methods of treating a metabolic disorder in an individual in need thereof, comprising co-administering to the individual a therapeutically effective amount of an FXR modulator, and at least one second agent that is an CCR2/CCR5 antagonist, ASK1 inhibitor, DPP-IV inhibitor, caspase protease inhibitor, SGLT2 inhibitor, acetyl-CoA carboxylase (ACC) inhibitor, diacylglycerol acyltransferase-1 inhibitor, sodium-bile acid cotransporter-inhibitor, TLR-4 antagonist, PPAR alpha/delta agonist, or GLP-1 agonist, or a combination thereof.

Abstract: Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.

Abstract: Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.

Abstract: Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.

Abstract: Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.

Abstract: A compound having the Formula (I), or a pharmaceutically acceptable salt or solvate thereof:

Abstract: Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.

Abstract: Described herein are fused bicyclic compounds, compositions, and methods for their preparation.